Navigation Links
Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation
Date:6/24/2009

assess whether cranial irradiation would have made a difference in CNS relapse, they compared the outcomes of 71 patients whose leukemias would have qualified them for irradiation with the outcomes of 56 patients who had received such irradiation in the past. The researchers found that the 71 patients, in fact, had significantly better complete remission than the 56 patients who had been irradiated.

"The bottom line is that not only did we get outstanding treatment responses in these patients, many of whom would have otherwise received irradiation, but they will have a better quality of life because of the absence of its side effects," Pui said.

"In a way, these findings represent coming full circle," said Dr. William Evans, St. Jude director and CEO and a co-author of the paper. "St. Jude was the first to introduce cranial radiation as a treatment strategy that advanced the cure of childhood ALL to 50 percent. Now, St. Jude is the first to show that we can successfully eliminate irradiation by optimizing chemotherapy."

Other authors of this paper include Deqing Pei, John Sandlund, Sue Kaste, Raul Ribeiro, Jeffrey Rubnitz, Susana Raimondi, Mihaela Onciu, Elaine Coustan-Smith, Larry Kun, Sima Jeha, Cheng Cheng, Scott Howard, Vickey Simmons, Monika Metzger, James Boyett, Wing Leung and James Downing (St. Jude); W. Paul Bowman and Amy Bayles (Cook Children's Medical Center); and Rupert Handgretinger (formerly of St. Jude).

The research was supported in part by the National Institutes of Health, the American Cancer Society F.M. Kirby Clinical Research Professorship and ALSAC.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Ten
'/>"/>

SOURCE St. Jude Children's Research Hospital
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
5. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
8. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
9. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
10. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
11. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... , Nov. 18, 2014  A new global ... finds that a large majority of the general public ... (84%), a devastating disease that is responsible for 1.59 ... cancers combined 1,2,4 . The "Any One Any Lung" ... about the widespread impact of lung cancer, but also ...
(Date:11/18/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... receipt of approval from the U.S. Food and Drug ... IMPLANT ® Saline-filled Breast Implant for ... augmentation implants. The FDA approval of the IDEAL IMPLANT ... and data including a U.S. clinical trial that began ...
(Date:11/18/2014)... Tocagen Inc. today announced that ... free survival at six months for recurrent high grade ... FC, compared to published benchmarks. HGG includes glioblastoma, the ... The data were delivered in an oral presentation at the ... of the Society for Neuro-Oncology (SNO) by Tim ...
Breaking Medicine Technology:Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 2Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 3Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 4Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 5Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 6Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 2Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 3Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 2Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 3Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 4Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 5
... May 16 Pulmo BioTech Inc. (OTC,Bulletin Board: PLMO.OB) ... Phase I Human Trials with its PulmoBind Molecular Imaging,technology ... The work will be carried out by the Pulmo ... is: "Phase I Study of the Use,of PulmoBind for ...
... -- Results demonstrating that TYKERB and trastuzumab ... survival (PFS), -- Combining TYKERB and trastuzumab ... HER2 receptor may create a more complete HER2 ... alone despite patients,previous treatment with multiple lines of ...
Cached Medicine Technology:Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7
(Date:11/18/2014)... 18, 2014 Cristcot Inc., a ... and commercialization of specialized drug delivery systems, today ... Cristcot a patent for the technology, which encompasses ... , The patent was awarded to the ... have been assigned to Cristcot Inc. The patented ...
(Date:11/18/2014)... 18, 2014 Medicationdiscountcard.com's ... adding to the company's reputation for helping consumers ... blog has to offer at http://blog.medicationdiscountcard.com/ . ... information concerning the Affordable Care Act and the ... inform the public about a variety of prescription ...
(Date:11/18/2014)... Thompson HealthDay Reporter ... antibody drug could prove effective at lowering LDL ("bad") ... cholesterol-lowering statin medications. That,s the conclusion of a ... annual meeting in Chicago. The drug, alirocumab, outperformed ... used alternative to statins, Zetia, said lead researcher Dr. ...
(Date:11/18/2014)... (HealthDay News) -- Women who started smoking at a ... severe menstrual pain, a new study suggests. About ... smoking has been suspected as a risk factor for ... authors of the new study said. The researchers ... long-term study of women,s health in Australia. About 14 ...
(Date:11/18/2014)... November 18, 2014 Global ... using the telehealth platform to bring quality healthcare ... this passion, GPT created Global Partnership for TeleHealth ... already existing telehealth network. GPTM focuses specifically ... overseas, and disaster relief organizations. , ...
Breaking Medicine News(10 mins):Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Medicationdiscountcard.com Building Virtual Library of Resources to Help Consumers Navigate Healthcare Landscape 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 3Health News:Study Ties Teen Smoking to Risk of Severe Menstrual Cramps 2Health News:Global Partnership for TeleHealth (GPT) is Focused on Using the telehealth Platform to Bring Quality Healthcare to Populations in Need Worldwide 2
... from Shropshire and parts of Wales. Breast cancer patients from ... but Welsh women get it for free. // ,This ... to pay for Herceptin for early stage breast cancer sufferers ... the welsh as all Welsh Local Health Boards have agreed ...
... in the capital of Zagreb it was revealed that a dead ... flu virus. //, ,The location of the dead swan was ... weekend. Tests confirmed that the dead bird had contracted the H5 ... it was the lethal H5N1 strain would be released on Sunday ...
... simulated investment game, a study, intending to investigate ... working //collectively in a team, revealed stark observations ... conducted by the University of Erfurt team, found ... when ‘punishments’ became a form of motivation. Psychologists ...
... nations should be prepared to pledge more money to combat ... ,Western and Asian donors had pledged $1.9 billion ... flu and improve containment and prevention methods in 12 countries, ... spreading across the world through migratory birds, including infections in ...
... should avoid exposure to the fumes of solvents used ... and lacquers//, could give rise to allergies in young ... Germany's environmental agency. ,Pregnant women should leave ... stay clear of the work area altogether. ...
... has warned the nation's betel-nut chewers of the increased ... habits like smoking and drinking. ,According to ... National Health Research Institute when betel nut chewing was ... cancer of the esophagus was about 195 times higher ...
Cached Medicine News:Health News:Free Herceptin Treatment for Those Who Live Over the Welsh Border 2Health News:Motivation Yardstick: Rewards or Punishment? Discover the Superior Performance Trigger 2Health News:Cancer Risks for Betel Nut Chewers 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: